In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 25, No. 18_suppl ( 2007-06-20), p. 1093-1093
Abstract:
1093 Background: Treating heavily pretreated metastatic breast cancer patients is challenging. To evaluate the activity and toxicity of the combination of capecitabine and cisplatin (CapCisp) in antracycline and taxane pretreated metastatic breast carcinoma (MBC) patients was the aim of our study. Methods: Thirty-three female MBC patients, 20 to 61 years of age (median; 41) were included in the study. Patients received Cap 2x1000 mg/m 2 on days 1–14, and Cisp 60 mg/m 2 on day 1, repeated every 3 weeks. In the case of disease control without intolerable toxicity, single agent Cap was continued. Results: Infiltrative ductal carcinoma was the most common histology (88%). In 23 patients with assigned histological grade, 13% had grade 1, 48% grade 2, and 39% grade 3 disease. Estrogen receptor (ER), Progesteron receptor (PR), and c-ErbB2 were positive in 39%, 63%, and 42%, respectively. All patients were pretreated with antracycline and taxane on an adjuvant or palliative basis before CapCisp chemotherapy. Altogether were given 154 courses of CapCisp chemotherapy (range; 1–8 courses per patient, median; 5 courses). Disease control rate was 82% (complete response, n: 1; partial response, n:16, stable disease, n: 10, progressive disease, n: 6). Eleven patients continued with single agent Cap (median; 4, range; 3–6 cycles). Grade 1 and 2 nausea/vomiting (66.7%) and fatigue (60.6%) were the most frequently observed side effects. Grade 3 neutropenia was observed in 4 patients (12.1%). Median follow-up was 9.5 months or until death. Median duration of response was 5.1 months (3.2–6.9, %95 CI). Median time to disease progression was 6.3 months (3.8–8.8, %95 CI). Fifteen patients died, and median survival was 11.5 months (6.9–16.1, 95% CI). Conclusion: CapCispl doublet has an encouraging antitumor activity with acceptable and manageable toxicity in antracycline and taxane pretreated metastatic breast carcinoma patients. No significant financial relationships to disclose.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/jco.2007.25.18_suppl.1093
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2007
detail.hit.zdb_id:
2005181-5
Permalink